Eli Lilly to test cancer drugs with Merck's Keytruda and BMS's Opdivo; Portola Pharmaceuticals kicks off PhIV study aimed at FDA approval;

@FiercePharma: ICYMI: Is once-skeptical J&J coming around on pharma's breakup craze? More | Follow @FiercePharma

@CarlyHFierce: Merck CEO Frazier credits Keytruda success to slim-down strategy. Article | Follow @CarlyHFierce

> Eli Lilly ($LLY) inked two separate deals with Merck ($MRK) and Bristol-Myers Squibb ($BMY) to test its approved and experimental cancer treatments in combination with Merck's Keytruda and BMS's Opdivo. Story

> Portola Pharmaceuticals ($PTLA) launched a Phase IV study aimed at FDA approval for its adexanet alfa Factor Xa inhibitor antidote. More

> The FDA created a new department, the Office of Pharmaceutical Quality, to monitor drug quality control at pharmaceutical manufacturing facilities. Story

> U.S. regulators are taking a hard look at extended-release drugs from companies such as Teva Pharmaceutical Industries ($TEVA) and Wockhardt ($WPL). More

> China's Guangzhou Baiyunshan Pharmaceutical's shares surged in Hong Kong trading after the company announced plans to raise as much as 10 billion yuan ($1.6 billion) by selling shares to investors. Article

> The FDA banned a batch of Eli Lilly's Cialis pills from an plant in Australia after regulators found that they contained the active ingredient for Pfizer's ($PFE) rival erectile dysfunction drug Viagra. Story

Medical Device News

@FierceMedDev: Roche snatches up majority share in Foundation Medicine for $1B plus milestones. Report from FierceDiagnostics | Follow @FierceMedDev

@StacyALawrence: ICYMI yesterday: JP Morgan: With $1.5B spent and a new president, NantHealth works to rationalize patient care. Article | Follow @StacyALawrence

> Biodesix bags $12M in Series E financing for blood-based lung cancer Dx. Story

> Roundup: Device companies announce new financing during JP Morgan confab

> Sleep apnea player Inspire Medical targets reimbursement to bolster launch. Article

Biotech News

@FierceBiotech: $ALNY and $ISIS strengthen RNAi alliance, agree to swap IP. FierceDrugDelivery article | Follow @FierceBiotech

@JohnCFierce: Last night I had to hug a wall to allow a stampede of biotech execs to surround the NY Times' Pollack. Dangerous work here at #JPM15. | Follow @JohnCFierce

> FDA steps in after a patient on Antares' 'low-T' drug breaks out in hives. Story

> Roche inks a $750M antibiotics deal as it re-embraces the field. Article

Biotech Research News

> Investigators electrify antibiotic R&D field with claims of a breakthrough. News

> Team takes a new approach to taming neuroinflammation. Article

> Amgen teams with MD Anderson on new BiTE programs for MDS. Story

> Scientists uncover new target for triple-negative breast cancer. Article

> Scripps researchers find a better way to make a nicotine vaccine. Report

Pharma Manufacturing News

> FDA upgrades Fresenius sterile plant once cited for insect infestation. Story

> AmerisourceBergen moving into vet drug distribution with $2.5B deal for MWI. News

> Group wants FDA to include Indian regulators on plant visits. More

> FDA stops import of Lilly's Cialis from Australia but Lilly says it doesn't make it there. Story

> AMRI buys more manufacturing capacity with deal for two Aptuit facilities. Article

And Finally… Aetna is planning to boost the incomes of its lowest-paid workers by as much as a third to attract promising candidates and reduce job turnover. Story (sub. req.)

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…